ArticleCureus2025
Efficacy of Debridement, Antibiotics, and Implant Retention for Periprosthetic Joint Infections Following Hip and Knee Arthroplasty: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Harnessing gasotransmitters for orthopaedic infection therapy: Mechanisms and advanced delivery platforms.Bioactive materials · 2027Review
- Timing from admission to debridement, antibiotic, and implant retention (DAIR) affects mortality risk in total hip prosthetic joint infections.Journal of bone and joint infection · 2026Article
- Review of Recent Advances in Managing Periprosthetic Joint Infection After Total Knee Arthroplasty: DAIR Technique.Orthopedic research and reviews · 2026Review
- Integrating Super-Oxidised Solutions into Multimodal Strategies for Orthopaedic Infection Prevention and Management.Cureus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to determine how well debridement, antibiotics, and implant retention (DAIR) work for treating infections after total hip and knee replacements. Specifically, it compared the success of this treatment in resolving infection, improving function, and preventing complications when the infection occurred early (within three months) versus late (three months to 12 months) after the joint replacement surgery.
objectiveThe objective of the study is to evaluate DAIR's efficacy in resolving periprosthetic joint infections (PJIs) post-THAs (total hip arthroplasties) and TKAs (total knee arthroplasties), focusing on infection resolution, functional recovery, and complications.
methodsThis retrospective cohort study reviewed 37 patients (25 TKA, 12 THA) treated with DAIR for PJIs at the UK tertiary centre (2019-2023). PJIs were diagnosed using the 2018 International Consensus Meeting (ICM) criteria.Outcomes (infection status, range of motion (ROM), pain, complications) were assessed via electronic health records, with a mean follow-up of 12.8 months for TKA and 10.4 months for THA. The statistical analysis tool used was IBM SPSS Statistics for Windows, Version 26 (Released 2019; IBM Corp., Armonk, New York, United States).
resultsDAIR successfully treated infection in 73.9% of infected total knee replacements and 58.3% of infected total hip replacements (p=0.576). Early infections (within three months) responded better to DAIR (88% for TKA, 91.7% for THA) compared to late infections (0% success, p<0.01). Complications arose in nine TKA and eight THA patients (p=0.157), including three deaths, which were more frequent in late infections (p=0.04). Following DAIR, there were significant reductions in average C-reactive protein levels for both TKA (from 134.5 to 16.9 mg/L, p<0.01) and THA (from 147.1 to 41.6 mg/L, p = 0.03).
conclusionDAIR achieved infection resolution in 73.9% of TKA and 58.3% of THA cases, particularly when performed within three months of infection onset, while late infections (>three months) had 0% success, emphasising the need for timely intervention and patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.